Treatment Sequence After First-Line Nivolumab Plus Ipilimumab Or Sunitinib Monotherapy In Patients With Metastatic Renal Cell Carcinoma (Mrcc) Using Real-World Data.

Daniel M. Geynisman,Jillian Faccone,Ying Zhang,Flavia Ejzykowicz,Brian Stwalley,Melissa Hamilton,Trong Kim Le,Stephen Huo

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 1|浏览5

暂无评分

摘要

288Background: The introduction of second-line (2L) nivolumab (NIVO) in 2015 (CheckMate 025) and first-line (1L) NIVO plus ipilimumab (NIVO+IPI) in 2018 (CheckMate 214) revolutionized the managemen...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要